Dr Matt Richardson is a clinical psychologist / neuropsychologist working at the ISIS Centre in Dunedin, New Zealand (a regional neurorehabilitation unit), in a full-time clinical post.
He was born and trained in the UK, gaining his Bachelor’s psychology degree from the University of St Andrews (Scotland), and his clinical doctorate at University College London (2001). He moved to New Zealand in 2008, and soon started working with patients with functional neurological symptoms for the first time. He quickly became disenchanted with somatisation/conversion explanations, and devised a new treatment in 2011, which achieved full symptom remission in all of the initial patients that he used it with. He went on to publish the subsequent consecutive case series, which achieved 93% full remission of a range of functional neurological symptoms.
Since publication in early 2018, he has been training others in his treatment protocol, now named Nocebo Hypothesis Cognitive Behavioural Therapy (NH-CBT) including an extensive workshop at the Australian College of Clinical Neuropsychologists’ annual conference, as well as multiple national workshops in all major New Zealand cities.
He also practices sports psychology, and currently works with New Zealand #1’s in two different sports, including golfer Ryan Fox.
Brett Langley completed his PhD in Molecular Medicine from the University of Auckland. After postdoctoral work at Harvard Medical School in Boston, he joined the Faculty of Neurology and Neuroscience at Weill Medical College of Cornell University in New York, becoming an Associate Professor, the Director of Neural Epigenetics, and the Director of Preclinical Traumatic Brain Injury. He is now an Associate Professor and Associate Dean Research at the University of Waikato.
Brett’s research is focused on understanding the molecular events that determine a neuron’s fate following injury or during disease, and ultimately, whether they can be modulated therapeutically to promote better outcomes in patients. A part of this research focuses on the degeneration and regeneration of a neuron’s axon. He investigates epigenetic and protein post-translational modifications that establish an axon’s stability, intrinsic growth rate, and its response to extrinsic negative growth cues in both central and peripheral nervous systems. The other part of Brett’s research focuses on neuronal DNA damage as a consequence of injury or neurodegenerative disease and how to engage mechanisms of DNA repair to facilitate survival. Together these studies move from genes and molecules, to cells, to animals, and eventually humans.
Consultant neuroradiologist at Waikato Hospital New Zealand, also working at two private imaging practices, Midland MRI and Hamilton Radiology. Current research interests include Spectral CT in stroke imaging and iodine concentration in squamous cell nodal disease of the head and neck.
In his spare time, he is an avid hiker/tramper, loves the outdoors including landscape photography, and is a part time conservationist developing an extensive area of native tree planting along the Mangaone gully in Tamahere, New Zealand.
Sanofi is dedicated to supporting people through their health challenges.
We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide self-care solutions to better manage personal wellbeing and provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.
One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Biogen today has the leading portfolio of medicines to treat multiple sclerosis (MS), has introduced the first and only approved treatment for spinal muscular atrophy, and is focused on advancing neuroscience research programs in MS and neuroimmunology, Alzheimer’s disease and dementia, movement disorders, neuromuscular disorders, acute neurology, neurocognitive disorders, pain, and ophthalmology.
Allergan is a global, technology-driven, multi-specialty health care company pursuing therapeutic advances to help patients live life to their fullest potential.Founded in 1950 and headquartered in Dublin, Ireland, Allergan Inc is a pharmaceutical, biologics and medical devices company. Allergan Australia Pty Ltd was first established in Sydney in 1968. Allergan employs more than 210 employees across Australia and New Zealand. Our product offerings focus on the areas of Neurosciences, Urology, Dermatology, Eye Care and Medical Aesthetics.
Ipsen provides specialty medicines and quality services to Healthcare Professional and their patients suffering from debilitating diseases.
At Ipsen, our passion is improving the lives of patients. We do this by working together to build partnerships based on trust and mutual respect with Healthcare Professionals. We deliver tailored solutions through our agility and innovation and we strive to be even better tomorrow than we are today.
Ipsen Pty Ltd is the Australian affiliate of a global R & D focused pharmaceutical company.
The Neurological Foundation is a charity that funds research and education into neurological disorders in New Zealand through donations from the public. Over the past five years, we have been able to fund over $13 million towards research and education including academic and clinical research projects, scholarships, fellowships, the Chair of Clinical Neurology and the Neurological Foundation Human Brain Bank.
It is becoming more and more important to make people aware of the impact these conditions can have. With 1 in 5 New Zealanders affected by a neurological condition, across people of all ages, we need to increase awareness of the 1100 plus neurological conditions, as well as the potential benefits available through research and education.
To find out how you can support us, or for more information on research and education opportunities, please visit us at neurological.org.nz
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, rheumatology and multiple sclerosis. Roche is also the world leader in in-vitro diagnostics and tissue-based cancer diagnostics. Roche New Zealand is based in Auckland and has a team dedicated to the goal of facilitating patient access to innovative medicines.
For more information on our medicines visit www.roche-plus.co.n
Seqirus (NZ) Ltd markets vaccines and pharmaceutical products in New Zealand, with a focus on products for the prevention and treatment of serious disease.
We also in-license a number of products from partner companies to broaden the range of products available to New Zealanders.
Through our partnership with UCB Pharma, Seqirus is the New Zealand distributor for UCB’s medicines to treat epilepsy.
STADA Australia and Britannia Pharmaceuticals are wholly owned subsidiaries of STADA Arzneimittel AG, the German-based company with over 120 years heritage in pharmaceuticals. STADA Australia and Britannia, the Originator of Apomorphine, are now working together to supply apomorphine directly to New Zealand.
We are committed to supporting patients and healthcare professionals through our team of Hospital Specialist Representatives and Nurse Advisors, and look forward to working closely with you to help deliver the optimal level of care for people with Parkinson’s, and directly delivering exciting new developments and improvements in Parkinson’s therapy.
Please contact STADA on (02) 9452 6656 for more information.